Baseline predictors of discontinuing treatment with tumour necrosis factor α inhibitors
| Unadjusted analysis | Adjusted analysis | Final model after backwards selection | |||||
|---|---|---|---|---|---|---|---|
| HR | p Value | HR | p Value | HR | p Value | ||
| Sex | Man | 1 | – | 1 | – | 1 | – |
| Woman | 1.96 (1.55 to 2.45) | <0.0001 | 1.46 (1.06 to 2.01) | 0.02 | 1.46 (1.07 to 2.00) | 0.02 | |
| BASDAI (cm) | 1.12 (1.05 to 1.20) | 0.001 | 0.97 (0.86 to 1.10) | 0.64 | – | – | |
| BASFI (cm) | 1.10 (1.04 to 1.17) | 0.002 | 1.06 (0.97 to 1.16) | 0.17 | – | – | |
| VAS fatigue (cm) | 1.15 (1.08 to 1.23) | <0.001 | 1.13 (1.03 to 1.24) | 0.009 | 1.14 (1.06 to 1.22) | <0.001 | |
| VAS pain (cm) | 1.07 (1.01 to 1.13) | 0.02 | – | – | – | – | |
| VAS global (cm) | 1.07 (1.01 to 1.13) | 0.03 | – | – | – | – | |
| CRP | ≤14 mg/l | 1.70 (1.33 to 2.12) | <0.0001 | 1.53 (1.13 to 2.07) | 0.006 | 1.53 (1.14 to 2.05) | 0.05 |
| >14 mg/l | 1 | – | 1 | – | 1 | – | |
| Methotrexate use | Used | 1 | – | 1 | – | – | – |
| Not used | 1.17 (0.93 to 1.47) | 0.18 | 1.35 (0.98 to 1.86) | 0.07 | – | – | |
| Biological treatment | Infliximab | 1 | – | 1 | – | – | – |
| Adalimumab | 0.86 (0.66 to 1.13) | 0.29 | 0.73 (0.49 to 1.10) | 0.13 | – | – | |
| Etanercept | 0.77 (0.57 to 1.05) | 0.09 | 0.71 (0.48 to 1.06) | 0.09 | – | – | |
| Age (years) | 1.01 (1.00 to 1.02) | 0.05 | 1.01 (0.99 to 1.02) | 0.41 | – | – | |
Numbers in brackets are 95% CI.
Results from multiple Cox regression analysis (n=842).
BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, function index; CRP, C-reactive protein.